Peter Olofsson, MBA, PhD
Member of the Board
Dr. Peter Olofsson was between 2007 and April 2016 CEO of Redoxis AB. Peter holds a PhD from Lund University and an executive MBA from the Göteborg School of Economics and Law and has previously held research positions at companies such as Arexis AB and Biovitrum AB (publ). Dr Olofsson also holds a research affiliation at the Karolinska Institute in Stockholm and engaged as external business advisor at Sahlgrenska Science Park. Since May 2016, Dr. Olofsson is the CEO and a member of the board of Redoxis subsidiary ProNoxis AB, focusing on development of small molecule drugs for treatment of autoimmune conditions.